Dalzanemdor

Dalzanemdor
Clinical data
Other namesSAGE-718
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • (3S,8R,9S,10R,13R,14S,17R)-3,13-Dimethyl-17-[(2R,5S)-6,6,6-trifluoro-5-hydroxy-5-methylhexan-2-yl]-2,4,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
CAS Number
PubChem CID
KEGG
Chemical and physical data
FormulaC26H41F3O2
Molar mass442.607 g·mol−1

Dalzanemdor (INN;[1] development code SAGE-718) is experimental drug being investigated for the treatment of neurological disorders and cognitive impairment.[2] It acts as a positive allosteric modulator of the NMDA receptor, whose activity is essential for learning, memory, and cognition.[3] Dalzanemdor is an analog of the neurosteroid 24S-hydroxycholesterol.[3]

As of 2022, dalzanemdor is in Phase II clinical trials[3] for Alzheimer's disease,[4][5][6] Parkinson's disease, and Huntington's disease.[7][8]

References

  1. ↑ "Investigational SAGE-718 Granted Nonproprietary Name of Dalzanemdor". Sage Therapeutics. December 5, 2023.
  2. ↑ Hill MD, Blanco MJ, Salituro FG, Bai Z, Beckley JT, Ackley MA, et al. (July 2022). "SAGE-718: A First-in-Class N-Methyl-d-Aspartate Receptor Positive Allosteric Modulator for the Potential Treatment of Cognitive Impairment". Journal of Medicinal Chemistry. 65 (13): 9063–9075. doi:10.1021/acs.jmedchem.2c00313. PMID 35785990. S2CID 250250073.
  3. 1 2 3 "SAGE-718". ALZFORUM.
  4. ↑ Shapiro L (5 April 2022). "#AAN2022 – SAGE-718 May Help With Cognitive Function in Alzheimer's". BioNews, Inc.
  5. ↑ "SAGE-718 in Patients With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease: Results From the Phase 2 LUMINARY Study" (PDF). American Academy of Neurology (AAN) 74th Annual Meeting Abstract.
  6. ↑ Castañeda R (16 November 2021). "Regulatory roundup: Sage Alzheimer's asset likely to progress after Phase IIa completion". Clinical Trials Arena. Archived from the original on 28 May 2022. Retrieved 13 July 2022.
  7. ↑ "Sage Therapeutics Provides Important Update On The Clinical Development Program For Sage's Investigational Drug, SAGE-718". Huntington's Disease Society of America. 22 February 2022.
  8. ↑ Wexler M (21 September 2021). "SAGE-718 on FDA Fast Track as Potential Huntington's Disease Therapy". BioNews, Inc.


This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.